Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

  1. Home
  2. /Clinical
  3. /Phase II

Clinical

Phase II(50)

Follow pivotal data releases and trial developments that create new strategic pressure for biotech and pharma operators.

50 signals

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

ScoreIntelligence Record
7.0

CLINICAL

Phase II Study of Alpelisib in PIK3CA-related Overgrowth Spectrum Initiated

A Phase II single-arm study is underway to evaluate the efficacy and safety of alpelisib in patients with PROS.

Alpelisib·August 2, 2026
7.0

CLINICAL

Phase II Trial on Adaptive Radiation Planning in NSCLC to Reduce Toxicity

A phase II trial is investigating adaptive radiation planning to minimize side effects in patients with stage II-IV non-small cell lung cancer.

Phase·August 2, 2026
7.0

COMPETITIVE

Phase 2 Study of PIPE-791 in Idiopathic Pulmonary Fibrosis Initiated by Contineum Therapeutics

Contineum Therapeutics has initiated Phase 2 trial to assess PIPE-791 in patients with Idiopathic Pulmonary Fibrosis.

Contineum Therapeutics·PIPE-791·August 2, 2026
7.0

CLINICAL

Phase II Study on HIPEC's Impact on PD-L1 in Advanced Gastric Cancer

The study aims to evaluate the upregulation of PD-L1 expression in peritoneal metastases from gastric cancer following HIPEC treatment.

Phase·August 2, 2026
7.0

CLINICAL

Phase II Trial of Nivolumab and Cabozantinib for Mucosal Melanoma Recurrence Prevention

A phase II trial is underway to evaluate the efficacy of nivolumab alone or in combination with cabozantinib in preventing mucosal melanoma recurrence post-surgery.

Nivolumab·August 1, 2026
8.0

CLINICAL

Phase II/III Trial of Atezolizumab with Chemotherapy for Advanced Neuroendocrine Carcinomas

A phase II/III trial is evaluating the efficacy of atezolizumab combined with standard chemotherapy in advanced or metastatic neuroendocrine carcinomas originating outside the lung.

Atezolizumab·August 1, 2026
7.0

CLINICAL

Phase II Trial of Cabazitaxel, Carboplatin, and Cetrelimab for Aggressive Variant Prostate Cancer

A phase II trial is investigating the combination of cabazitaxel, carboplatin, and cetrelimab followed by niraparib in patients with metastatic aggressive variant prostate cancer.

cetrelimab·August 1, 2026
7.0

CLINICAL

Phase II Trial of Blinatumomab with Nivolumab in Relapsed B-ALL Patients

This phase II trial compares the efficacy of nivolumab combined with blinatumomab versus blinatumomab alone in relapsed B-ALL patients.

Blinatumomab·July 31, 2026
7.0

CLINICAL

Phase II Trial of Nivolumab and Ipilimumab in Kidney Transplant Recipients with Metastatic Skin Cancer

A phase II trial is underway testing nivolumab and ipilimumab combined with sirolimus and prednisone in kidney transplant recipients with unresectable or metastatic skin cancer.

Nivolumab·July 31, 2026
7.0

CLINICAL

Phase 2 Study of Poziotinib in NSCLC with EGFR/HER2 Mutations Underway

A Phase 2 study is evaluating poziotinib's efficacy and safety in NSCLC patients with specific mutations.

Poziotinib·July 30, 2026
7.0

CLINICAL

Ibrutinib and Rituximab Show Promise in Relapsed/Refractory Mantle Cell Lymphoma

A phase II trial is investigating the efficacy of ibrutinib and rituximab in treating relapsed or refractory mantle cell lymphoma.

Ibrutinib·July 30, 2026
7.0

CLINICAL

Phase II/III Trial of Haloperidol and Lorazepam for Agitated Delirium in Advanced Cancer Patients

A phase II/III trial is evaluating the efficacy of haloperidol and lorazepam in managing persistent agitated delirium in advanced cancer patients receiving palliative care.

Phase·July 30, 2026
8.0

CLINICAL

Phase II/III Trial of BL-B01D1 with Osimertinib in EGFR-mutant NSCLC Initiated

A Phase II/III trial has been initiated to evaluate BL-B01D1 combined with osimertinib in patients with resectable EGFR-mutant non-small cell lung cancer.

Sichuan Baili Pharmaceutical Co., Ltd.·osimertinib·July 29, 2026
7.0

CLINICAL

Phase II Trial of Paclitaxel and Cixutumumab in Metastatic Esophageal Cancer

A randomized phase II trial is evaluating the efficacy of paclitaxel with or without cixutumumab in metastatic esophageal cancer.

Paclitaxel·July 28, 2026
7.0

CLINICAL

Phase II Study Links Chronic Hypoxia to Multiple System Atrophy Risk in Han Chinese

The High-Altitude Neurodegeneration Cohort study aims to validate the link between chronic hypoxia and multiple system atrophy (MSA) risk in a large cohort of Han Chinese participants.

Phase·July 27, 2026
7.0

CLINICAL

Phase II Trial Evaluates Chemo and Chemo-Immunotherapy for Advanced Head and Neck Cancer

A phase II trial is testing the addition of chemotherapy or chemo-immunotherapy to standard salvage surgery for PD-L1 positive head and neck squamous cell carcinoma.

cemiplimab·July 26, 2026
7.0

CLINICAL

Phase II Study of BL-B01D1 with PD-1 Antibody in Advanced Lung Cancer and Other Tumors

A phase II clinical trial is underway to evaluate the efficacy and safety of BL-B01D1 in combination with PD-1 monoclonal antibody.

Sichuan Baili Pharmaceutical·Phase·July 25, 2026
7.0

CLINICAL

Phase 2 Study of Mosunetuzumab in CLL Patients Post-BTKi Treatment

A Phase 2 study is underway to evaluate the efficacy of mosunetuzumab in CLL patients with detectable disease after BTKi treatment.

Roche·mosunetuzumab·July 25, 2026
7.0

CLINICAL

Narlumosbart with SBRT shows promise in NSCLC with bone metastases in new Phase II trial

A Phase II trial is investigating narlumosbart, RANKL-targeting mAb, combined with SBRT and first-line chemotherapy/immunotherapy in NSCLC patients with bone metastases.

Narlumosbart·July 25, 2026
7.0

CLINICAL

Phase 2 Study on 124-I-PET/CT Dosimetry in High-Risk Differentiated Thyroid Cancer

A phase 2 pilot study is comparing 124 I-PET/CT dosimetry methods in patients with high-risk differentiated thyroid cancer.

Phase·July 22, 2026
7.0

CLINICAL

JNJ-79635322 Dose Escalation Study in Multiple Myeloma Shows Promising Combinations

The study aims to establish recommended Phase 2 doses for JNJ-79635322 in combination with daratumumab and other agents.

JNJ-79635322·Daratumumab·July 22, 2026
7.0

CLINICAL

JNJ-89402638 Phase 2 Study Initiated for Metastatic Colorectal and Gastric Cancers

A Phase 2 study is underway to assess the safety and optimal administration of JNJ-89402638 in mCRC and mGAC patients.

JNJ-89402638·bevacizumab·July 22, 2026
7.0

CLINICAL

Phase 2 Trial of Zanzalintinib in Advanced Bone Sarcomas Initiated

A Phase 2 trial is underway to evaluate the efficacy of zanzalintinib monotherapy in patients with advanced or metastatic bone sarcomas.

Zanzalintinib·July 22, 2026
7.0

CLINICAL

Phase II Trial Optimizes Therapy for HER2+ Breast Cancer Patients Post-Surgery

A Phase II trial is testing reduced adjuvant therapy for HER2+ breast cancer patients who achieved a pathologic complete response after neoadjuvant treatment.

trastuzumab·July 22, 2026
7.0

COMPETITIVE

Phase 2 Study of LTI-03 in Idiopathic Pulmonary Fibrosis Patients Initiated by Rein Therapeutics

Rein Therapeutics is conducting Phase 2 trial of LTI-03, an inhaled medication for IPF, comparing it to placebo.

Rein Therapeutics·LTI-03·July 21, 2026

Showing 1–25 of 50 records

Page 1 of 2